Molecular imaging is a powerful tool for advancing drug development programs. Imaging can be used exclusively in the nonclinical setting to answer biological questions regarding PKPD, target expression and engagement, and internalization and metabolism of novel therapeutics as well as the development of biomarker strategies.

The “translatability” of molecular imaging methodologies to the clinical setting allows for the development of biomarker-based companion diagnostics to support go/no-go decisions at early clinical phases. inviCRO’s combination of flexible, versatile and innovative nonclinical work together with highly specialized clinical imaging experience provide the perfect toolbox for research programs interested in quickly advancing their products into the clinical setting.